Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | PEPD | P12955 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL204377 | 1.00 | HSD17B10 (0.41) | HSD17B10HDAC8SMN1; SMN2PEPDCHRM2 | |
| SCHEMBL20811615 | 1.00 | HSD17B10 (0.41) | HSD17B10HDAC8SMN1; SMN2PEPDCHRM2 | |
| SCHEMBL23824234 | 0.94 | HSD17B10 (0.42) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL10138527 | 0.94 | HSD17B10 (0.42) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL24020735 | 0.94 | HSD17B10 (0.42) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL12604940 | 0.94 | HSD17B10 (0.42) | HSD17B10HDAC8SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL25333125 | 0.93 | HSD17B10 (0.37) | HSD17B10HDAC8SMN1; SMN2PEPDCHRM2 | |
| SCHEMBL23824537 | 0.93 | HSD17B10 (0.41) | HSD17B10HDAC8SMN1; SMN2EPHX2LMNA | |
| SCHEMBL24740635 | 0.93 | HSD17B10 (0.41) | HSD17B10HDAC8SMN1; SMN2EPHX2LMNA | |
| SCHEMBL24113141 | 0.93 | HSD17B10 (0.41) | HSD17B10HDAC8SMN1; SMN2EPHX2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 542 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111303007-B | Preparation method of (S) -5- (tert-butyloxycarbonyl) -5-azaspiro [2,4] heptane-6-carboxylic acid | 苏州楚凯药业有限公司 | 2022-03-08 | — | — | CN | claimed |
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12616682-B2 | 1-H-pyrrolo[2,3-c]pyridine compounds | ACERTA PHARMA B.V. (NL) | 2026-05-05 | — | — | US | disclosed |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-04-23 | — | — | US | disclosed |
| US-12577240-B2 | Antiviral heteroaryl ketone derivatives | PFIZER INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4688776-A1 | 1-H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS ACTING AGAINST CANCER VIA AGONISM OF MENIN | Acerta Pharma B.V. (NL) | 2026-02-11 | — | — | EP | disclosed |
| CN-121426732-A | Synthesis method of compound (S) -6- (methoxymethyl) -5-azaspiro [2.4] heptane hydrochloride | 上海毕得医药科技股份有限公司 | 2026-01-30 | — | — | CN | disclosed |
| WO-2011091417-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011081918-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| WO-2010099527-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2009102325-A1 | IMIDAZOLYL BIPHENYL IMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | HSD17B10 3161/4885HDAC8 1441/4885SMN1; SMN2 21/4885 |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | HSD17B10 906/4885HDAC8 59/4885SMN1; SMN2 3741/4885 |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | HSD17B10 1305/4885HDAC8 1638/4885SMN1; SMN2 4352/4885 |
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, HRAS | HSD17B10 1579/4885HDAC8 2008/4885SMN1; SMN2 4243/4885 |
| US-12577240-B2 | Antiviral heteroaryl ketone derivatives | ACE2, SARS1, ACE | HSD17B10 525/4885HDAC8 1531/4885SMN1; SMN2 1593/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | HSD17B10 1332/4885HDAC8 1126/4885SMN1; SMN2 4141/4885 |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | HSD17B10 581/4885HDAC8 740/4885SMN1; SMN2 4162/4885 |
| US-12616682-B2 | 1-H-pyrrolo[2,3-c]pyridine compounds | MEN1, PKD1, PKD2 | HSD17B10 3811/4885HDAC8 1182/4885SMN1; SMN2 121/4885 |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | HSD17B10 1168/4885HDAC8 602/4885SMN1; SMN2 881/4885 |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HSD17B10 3314/4885HDAC8 1196/4885SMN1; SMN2 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.